"Immunity and Inflammation Disease Treatment Research" Dong-A ST joins hands with Crystal Pie

[Financial News] Dong-A ST announced on the 20th that it has signed a Memorandum of Understanding (MOU) for joint research with Crystal Pie for the development of treatments for immune and inflammatory diseases.
This agreement will be based on Crystal Pie's intelligent automatic drug development platform, which integrates artificial intelligence (AI), quantum physics, and automated robotics technology. The two companies plan to use the platform for △deep learning-based molecular design △quantum physics and molecular dynamics simulations for predicting drug-target interactions △automated chemical synthesis △experimental verification of key pharmacological properties of candidate substances. Through this, they aim to discover new targets for immune and inflammatory diseases. They also plan to explore first-in-class and best-in-class candidate substances.
Dong-A ST will participate in the entire research and development process, including △evaluation of candidate substance feasibility △verification of efficacy and safety △establishment of preclinical and clinical development strategies. They will also review the possibility of pipeline expansion and commercialization in the future.
Dong-A ST and Crystal Pie are operating an open innovation center in Boston, USA. They plan to pursue close and efficient joint research on drug development by leveraging geographical advantages.
John Wang, Senior Vice President of Drug Development at Crystal Pie, said, "The combination of Dong-A ST's expertise and our proven AI-robotics platform is a combination that can translate scientific innovation into precision medicine."
Park Jae-hong, Head of Research and Development (R&D) at Dong-A ST, said, "We will accelerate the development of next-generation immune and inflammatory disease treatments through synergy with Crystal Pie's AI platform."


kaya@fnnews.com Choi Hye-rim Reporter